* CalciMedica Inc reported a quarterly adjusted loss of 23 cents per share for the quarter ended in December. The mean expectation of four analysts for the quarter was for a loss of 87 cents per share. Wall Street expected results to range from $-1.14 to -60 cents per share.
* Reported revenue was zero; analysts expected zero.
* CalciMedica Inc's reported EPS for the quarter was a loss of 23 cents.
* The company reported a quarterly loss of $4.15 million.
* CalciMedica Inc shares had risen by 46.5% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 14% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for CalciMedica Inc is $17.00 This summary was machine generated from LSEG data March 28 at 12:22 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.87 -0.23 Beat
Sep. 30 2023 -1.14 -0.82 Beat
Jun. 30 2023 -1.04 -1.11 Missed
Mar. 31 2023 -0.73 -23.43 Missed
Comments